Emerging roles of lipids in the modulation of cancer risk and therapy

By: DSM Nutritional Products

4 October 2017, 8:00 am MDT / 9:00 am CDT / 4:00 pm CET

Join us for our first webinar on omega-3 and oncology, presented by Dr. Catherine Field and Dr. Robert Chapkin, two of the world’s leading experts in the molecular mechanisms by which lipids modulate cancer risk and therapy. Together with DSM’s Dr. Keri Marshall, they will discuss the evidence for the use of omega-3 polyunsaturated fatty acids (PUFAs) as a part of neoadjuvant therapy for two of the most common cancers: breast and colon.

In 2017, there will be an estimated 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the US alone. By 2030, the global burden is expected to grow from 14.1 million new cancer cases and 8.2 million cancer deaths worldwide in 2012, to 21.7 million new cancer cases and 13 million cancer deaths, simply due to population growth and longer lifer spans. The future burden may be even larger due to the adoption of certain habits common in Western lifestyles, such as smoking, poor diet, and physical inactivity.

Omega-3 PUFAs such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been shown to play a role in both prevention and treatment of multiple forms of cancer. The webinar will explore the current state of the science for EPA and DHA as a bioactive, including novel research in human cell lines, that show evidence in preclinical models using patient derived xenographs. It will also provide an overview on the potential mechanisms as to how DHA may improve neoadjuvant chemotherapy, while protecting healthy cells.

Published on

07 September 2017


  • Events
  • Lipids
  • Event
  • R&D
  • Webinars


3 min read

Sign up for our newsletter

Stay up-to-date on the latest science, events and market trends

Download our Pharma Solutions Catalogue

Quick Links


Request samples, place orders and view product documentation


Download the latest copy of our Solutions Catalogue

Contact Us

We’re more than a partner. We’re a competitive edge.


The latest in vitamin and lipid research and industry developments


Academic studies and the latest science in educational modules


Videos exploring the growing role of vitamin APIs and lipid API intermediates